- Home
- ARWR vs PODD Comparison
ARWR vs PODD Comparison
Compare ARWR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARWR | PODD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.3B |
| IPO Year | 2009 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ARWR | PODD |
|---|---|---|
| Price | $73.89 | $163.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | $83.40 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.0M | 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | $16,142,321.00 | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | N/A | $19.18 |
| P/E Ratio | ★ N/A | $128.75 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $15.01 | $138.79 |
| 52 Week High | $87.83 | $354.88 |
Technical Indicators
Market Signals| Indicator | ARWR | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 56.16 |
| Support Level | $70.05 | $141.67 |
| Resistance Level | $77.39 | $164.59 |
| Average True Range (ATR) | 3.85 | 6.04 |
| MACD | -1.17 | 0.86 |
| Stochastic Oscillator | 22.34 | 65.00 |
Price Performance
Historical ComparisonAbout ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.